Patents Represented by Attorney, Agent or Law Firm David S. Resnick
  • Patent number: 5382519
    Abstract: Novel substantially pure periplasmic 3':5'-cyclic nucleotide phosphodiesterases are provided which are obtainable from gram negative bacterium capable of growing on restricted media containing cAMP or cGMP as a sole carbon source. Also provided is the isolated DNA coding for such enzymes and related methods of producing the same.
    Type: Grant
    Filed: January 13, 1993
    Date of Patent: January 17, 1995
    Assignee: Woods Hole Oceanographic Institution
    Inventors: Paul V. Dunlap, Sean M. Callahan
  • Patent number: 5371745
    Abstract: An error correction apparatus for reproducing data that have been multi-encoded with error correcting codes and recorded on a recording medium, and for correcting errors contained in the reproduced data through decoding the same. The apparatus includes: a reproducing circuit for reproducing the data encoded and recorded on the recording medium; a memory for storing the reproduced data; an error correction circuit adapted to correct errors of the data with the error correcting codes from the lowest to the highest levels in due order, for detecting that correction is impossible at the highest level and at an intermediate level between the lowest and the highest levels and for outputting a first and a second correction incapability detecting signals, respectively; and a controller responsive to the first and second correction incapability detecting signals for controlling the reproduction circuit, the memory and the error correction circuit.
    Type: Grant
    Filed: May 17, 1990
    Date of Patent: December 6, 1994
    Assignee: Sharp Kabushiki Kaisha
    Inventors: Chitoku Kiyonaga, Kengo Sudoh
  • Patent number: 5366882
    Abstract: In accordance with the present invention there is provided an isolated DNA coding for the Bg/I restriction endonuclease and modification methylase derived from Bacillus globigii RUB561 stain, as well as related methods for cloning said recombinant DNA. The present invention also relates to clones which express recombinant Bg/I restriction endonuclease and recombinant modification methylase produced from Bg/I recombinant DNA and to methods for producing said enzymes.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: November 22, 1994
    Assignee: New England Biolabs
    Inventors: Keith D. Lunnen, Geoffrey G. Wilson
  • Patent number: 5356311
    Abstract: A network wall plate includes a wall plate shell, a plurality of transmission-line adapting sockets removably installed on the wall plate shell, a plurality of transmission-line connectors which can be respectively plugged into the transmission-line adapting sockets, and two screw bases capable of passing therethrough screws to fix the wall plate onto a wall surface, wherein at least one of the transmission-line connectors can be removably plugged into one of the transmission-line adapting sockets. The present wall plate is designed to be diversified, to have an increased socket density and/or to provide an improved appearance.
    Type: Grant
    Filed: March 25, 1993
    Date of Patent: October 18, 1994
    Inventor: Danny Liu
  • Patent number: 5352778
    Abstract: Recombinant DNA polymeraset from archaebacteria as well as isolated DNA coding for such polymeraset are provided. The isolated DNA is obtained by use of DNA or antibody probet prepared from the DNA encoding T. litoralis DNA polymerate and the T. litoralis DNA polymerate respectively. Also provided are meshocs for producing recombinant archaebacteria thermostable DNA polymerase and methods for enhancing the expression of such polymeraset by identifying, locating and removing introns from within the DNA coding for such DNA polymerases.
    Type: Grant
    Filed: December 15, 1993
    Date of Patent: October 4, 1994
    Assignee: New England Biolabs, Inc.
    Inventors: Donald G. Comb, Francine Perler, Rebecca Kucera, William E. Jack
  • Patent number: 5348866
    Abstract: This invention relates to a DNA sequence comprising at least part of a porcine zona pellucida PZP-4.alpha. or -4.beta. gene coding for an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2, respectively, in SEQUENCE LISTING.This invention also relates to an expression system and to expression of said DNA.In addition, this invention relates to an immunogenic recombinant polypeptide or peptide which comprises at least part of said amino acid sequence and which is obtained by expressing said DNA, and to a contraceptive vaccine for use in human or other animals which comprises said polypeptide or peptide as an active ingredient.
    Type: Grant
    Filed: March 20, 1992
    Date of Patent: September 20, 1994
    Assignees: Shinzo Isojima, Tonen Corporation
    Inventors: Shinzo Isojima, Akiko Akatani, Yuichi Okazaki, Masanobu Sugimoto
  • Patent number: 5328986
    Abstract: A novel growth factor (BTC-GF) was purified from the conditioned medium of pancreatic beta tumor cells initially derived from transgenic mice (RIPI-Tag2). The purification scheme included BioRex 70 chromatography, phenyl-Sepharose chromatography, TSL-GEL heparin FPLC and C4 reverse phase HPLC. The peptide also stimulated proliferation of bovine smooth muscle cells. It was not inactivated by boiling, by 10 mM dithiothreitol or by exposure to 1M acetic acid. Biological activity of BTC-GF was recovered from a single band of protein which had a molecular weight of 32,000 on SDS-PAGE.
    Type: Grant
    Filed: February 10, 1992
    Date of Patent: July 12, 1994
    Assignee: Children's Medical Center Corporation
    Inventors: Moses J. Folkman, Yuen Shing
  • Patent number: 5324651
    Abstract: Human protein kinase C and rat protein kinase C, recombinant DNA containing DNA sequence coding for kinase C, a transformant transformed with a vector containing the above recombinant DNA, and the production method of human or rat kinase C by cultivating the transformant are disclosed.Kinase C is useful as reagent for studying cellular signal transduction mechanism, as diagnostic and inspection agent for disease, for example tumor, resulting from the trouble of cellular signal transduction mechanism, and as screening agent for a preventive agent or medicine to the disease.
    Type: Grant
    Filed: September 16, 1992
    Date of Patent: June 28, 1994
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Ono Yoshitaka, Kurokawa Tsutomu, Igarashi Koichi, Nishizuka Yasutomi
  • Patent number: 5322785
    Abstract: There is provided an extremely thermostable enzyme obtainable from Thermococcus litoralis. The thermostable enzyme has a molecular weight of about 90,000-95,000 daltons, a half-life of about 60 minutes at 100.degree. C. in the absence of stabilizer, and a half-life of about 95 minutes at 100.degree. C. in the presence of stabilizer, such as octoxynol (TRITON X-100) or bovine serum albumin. The thermostable enzyme possesses a 3'-5' proofreading exonuclease activity. The thermostable enzyme may be native or recombinant and may be used for second-strand cDNA synthesis in cDNA cloning, DNA sequencing, and DNA amplification.
    Type: Grant
    Filed: April 17, 1991
    Date of Patent: June 21, 1994
    Assignee: New England Biolabs, Inc.
    Inventors: Donald G. Comb, Francine Perler, Rebecca Kucera, William E. Jack
  • Patent number: 5306808
    Abstract: Disclosed are a peptide derivative represented by the formula [I] or a pharmaceutically acceptable salt thereof: ##STR1## wherein A, B, C, D, E and F each represent amino acid residues, and satisfy any one condition of (i) A=Ser, B=Ser, C=Ser, D=Leu, E=Met and F=Phe, (ii) A=Ser, B=Ser, C=Ser, D=Trp, E=Leu and F=Phe, and (iii) A=Thr, B=Phe, C=Thr, D=Tyr, E=Lys and F=Tyr; and W, X, Y and Z each represent amino acid residues, and satisfy any one condition of (i) at least one of W and Y is an amino acid residue other than an L-alanine residue or other than an L-cysteine residue, (ii) X is an amino acid residue other than an L-Lysine residue, and (iii) Z is an amino acid residue other than an L-aspartic acid residue; (2) a method for producing the peptide derivative or the salt thereof; and (3) an agent for improving a circulatory function mainly comprising the peptide derivative or the salt thereof, such as a vasodilator or a vasoconstrictor.
    Type: Grant
    Filed: October 17, 1991
    Date of Patent: April 26, 1994
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Mitsuhiro Wakimasu, Takashi Kikuchi, Kazuki Kubo
  • Patent number: 5298404
    Abstract: The present invention is directed to a method for cloning and producing the Hpa I restriction endonuclease by 1) introducing the restriction endonuclease gene from Haemophilus parainfluenzae into a host whereby the restriction gene is expressed; 2) fermenting the host which contains the vector encoding and expressing the Hpa I restriction endonuclease, and 3) purifying the Hpa I restriction endonuclease from the fermented host which contains the vector encoding and expressing the Hpa I restriction endonuclease activity.
    Type: Grant
    Filed: October 13, 1989
    Date of Patent: March 29, 1994
    Assignee: New England Biolabs, Inc.
    Inventors: Jack S. Benner, Phyllis Rees
  • Patent number: 5296371
    Abstract: The present invention is directed to a method for cloning and producing the Spiroplasma sp. strain MQ1 DNA methylase by (1) introducing the Spiroplasma methylase gene into a host whereby the methylase gene is expressed; (2) fermenting the host which contains the vector encoding and expressing the Spiroplasma methylase and (3) purifying the Spiroplasma methylase from the fermented host which contains the vector encoding and expressing the Spiroplasma DNA methylase activity.
    Type: Grant
    Filed: October 4, 1991
    Date of Patent: March 22, 1994
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem, an Israeli Corp.
    Inventors: Aharon Razin, Shlomo Rottem, Pinhas F. Renbaum
  • Patent number: 5290807
    Abstract: O-substituted fumagillol derivatives and its salts have an angiogenesis regressing activity are useful for treatment of diseases induced by abnormally stimulated neovascularization.
    Type: Grant
    Filed: July 21, 1992
    Date of Patent: March 1, 1994
    Assignee: Children's Medical Center Corporation
    Inventors: Moses J. Folkman, Donald Ingber
  • Patent number: 5288696
    Abstract: The present invention is directed to a method for cloning and producing the SacII restriction endonuclease by 1) introducing the restriction endonuclease gene from Streptomyces achromogenes into a host whereby the restriction gene is expressed; 2) fermenting the host which contains the plasmid encoding and expressing the SacII restriction endonuclease activity, and 3) purifying the SacII restriction endonuclease from the fermented host which contains the plasmid encoding and expressing the SacII restriction endonuclease activity.
    Type: Grant
    Filed: September 7, 1990
    Date of Patent: February 22, 1994
    Assignee: New England Biolabs, Inc.
    Inventors: Ellen P. Guthrie, Marta M. Meda
  • Patent number: 5288722
    Abstract: The present invention relates to a compound of the formula: ##STR1## wherein R.sup.1 is 2-methyl-1-propenyl group or isobutyl group; R.sup.2 and R.sup.3 are each hydrogen atom, an optionally substituted hydrocarbon residue or an optionally substituted acyl group or R.sup.2 and R.sup.3 may form a ring together with the adjacent nitrogen atom; and the bonding mark .about. represents an .alpha.-linkage or .beta.-linkage, or a salt thereof. The compound (I) of the present invention has, among others, angiogenesis inhibiting activity, cell-growth inhibiting activity and immune reaction inhibiting activity, thus being useful as medicines, etc.
    Type: Grant
    Filed: September 19, 1991
    Date of Patent: February 22, 1994
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Shoji Kishimoto, Shogo Marui, Takeshi Fujita
  • Patent number: 5248599
    Abstract: Disclosed is a DNA sequence containing a DNA segment coding for Achromobacter protease I (API) or variants thereof (referred to as T-API); a recombinant DNA constructed by introducing the DNA sequence in an expression vector so as to express the T-API; a transformant bearing the recombinant DNA; a process for producing the API which comprises cultivating the transformant, accumulating the T-API in a culture product, and recovering the same: and a protein of T-API. The cells transfected or transformed with the DNA sequence of the present invention allow for the production of a large amount of precursor protein of the T-API or the mature peptide.
    Type: Grant
    Filed: February 20, 1990
    Date of Patent: September 28, 1993
    Assignee: Waco Pure Chemical Industries, Ltd.
    Inventors: Fumio Sakiyama, Atsuo Nakata
  • Patent number: 5246845
    Abstract: The present invention provides a novel approach to the production of restriction enzymes. More specifically, there is provided a novel method for cloning these enzymes, which comprises preparing DNA libraries from the DNA of an organism that synthesizes the restriction enzyme of interest, creating a suitable host containing a heterospecific methyltransferase gene able to protectively modify DNA from digestion by the restriction enzyme of interest, introducing the DNA libraries into the protectively modified host, and screening recombinant organisms to identify those carrying the desired restriction enzyme gene.The application of this method to the FspI and HaeIII restriction genes of Fischerella species and Haemophilus aegyptius, respectively, is described in detail, together with the resulting clones that form the basis of a new and useful process for purifying the FspI and HaeIII restriction enzymes.
    Type: Grant
    Filed: October 27, 1992
    Date of Patent: September 21, 1993
    Assignee: New England Biolabs, Inc.
    Inventors: Geoffrey G. Wilson, Marta M. Meda
  • Patent number: 5242829
    Abstract: Monovalent and multivalent recombinant pox viruses which express immunogenic proteins of pseudorabies viruses are provided for use as live vaccines against pseudorabies virus. DNA vectors for recombination with pox virus to introduce one or more genes into a pox viral genome are also provided.
    Type: Grant
    Filed: March 6, 1990
    Date of Patent: September 7, 1993
    Assignee: Therion Biologics Corporation
    Inventors: Dennis L. Panicali, Gail P. Mazzara, Linda R. Gritz
  • Patent number: 5233015
    Abstract: High-molecular weight synthetic resins of polyhexamethylene adipates are disclosed with molecular weights greater than about 10,000, preferably greater than about 30,000, and a viscosity at 100.degree. C. of at least about 300 poise, preferably exceeding 6000.The polymerization is carried out with a ratio of diol/acid in the range 0.990 to about 1.03, preferably in the range of about 1.001 to about 1.01.
    Type: Grant
    Filed: March 21, 1991
    Date of Patent: August 3, 1993
    Assignee: Bostik, Inc.
    Inventors: Reginald T. Agger, Joginder S. Johl
  • Patent number: 5229493
    Abstract: A novel growth factor (BTC-CG) was purified from the conditioned medium of pancreatic beta tumor cells initially derived from transgenic mice (RIPl-Tag2). The purification scheme included BioRex 70 chromatography, phenyl-Sepharose chromatography, TSL-GEL heparin FPLC and C4 reverse phase HPLC. The peptide also stimulated proliferation of bovine smooth muscle cells. It was not inactivated by boiling, by 10 mM dithiothreitol or by exposure to IM acetic acid. Biological activity of BTC-GF was recovered from a single band of protein which had a molecular weight of 2,000 on SDS-PAGE. The Partial N-terminal amino acid sequence of this protein was determined with an ABI 470A protein sequencer as: Asp-Gly-[X]-Thr-[X]-Arg-Thr-Pro-Glu-[X]-Asn-Gly.
    Type: Grant
    Filed: October 26, 1990
    Date of Patent: July 20, 1993
    Assignee: Children's Medical Center Corporation
    Inventors: Moses J. Folkman, Yuen Shing